Profile picture of Yada Kanjanapan

Dr Yada Kanjanapan

Profile picture of Yada Kanjanapan

MBBS, FRACP

Medical Oncologist
Call
Enquire
Referrals

Dr Yada Kanjanapan is committed to delivering evidence-based care in collaboration with her multidisciplinary team of surgical and radiation oncologists.

Biography

Dr Yada Kanjanapan is an experienced medical oncologist at Icon Cancer Centre Canberra and a senior staff specialist at The Canberra Hospital. She obtained a Bachelor of Medicine and Bachelor of Surgery (MBBS) from the University of Adelaide and completed specialist oncology training at Canberra Hospital and Peter MacCallum Cancer Centre in Melbourne. Dr Kanjanapan subsequently completed a two-year clinical research fellowship in drug development, melanoma, and gynaecological cancers at the Princess Margaret Cancer Centre in Toronto, Canada. She held a medical oncology position at Sydney’s Prince of Wales Hospital where she managed a wide range of solid tumour malignancies.

Since returning to her hometown of Canberra, Dr Kanjanapan has been active in research, serving as a principal investigator in numerous clinical trials for breast and gynaecological cancers. Her research interests include breast cancer, immunotherapy, and developmental therapeutics, with a strong publication record. In 2018, Dr Kanjanapan was a recipient of an American Society of Clinical Oncology (ASCO) Merit Award. She is also a clinical Senior Lecturer at the Australian National University, teaching and mentoring medical students in clinical skills and research.

Dr Kanjanapan’s clinical experience covers a broad range of solid tumour malignancies with subspecialty expertise in breast cancer, gynaecological cancers, and skin cancers, particularly melanoma.

Publications

  • Real-world analysis of breast cancer patients qualifying for adjuvant CDK4/6 inhibitors, Clinical Breast Cancer. Kanjanapan Y, Anderson, W, Smith M, Green J, Chalker E, Craft P.  Clinical Breast Cancer, 2024.

  • Response to COVID-19 vaccination in patients on cancer therapy: Analysis in a SARS-CoV-2-naïve population. Cavic G, Almonte A, Hicks M, Neeman T, Wang JW, Brew S, Choi PY, Cockburn I, Gardiner E, Yip D, Fahrer A, Kanjanapan Y. Asia-Pacific Journal of Clinical Oncology, 2024.

  • Impact of prior (neo)adjuvant trastuzumab exposure on the efficacy of HER2 targeted therapy for metastatic breast cancer. Y. Kanjanapan,  D. Tran, S.W. Lok, P.Gibbs, R. De Boer, B. Yeo, S. Greenberg, F. Barnett, L. Nott, G. Richardson, R. Wong, M. Nottage, I. Collins, J. Torres, J. Lombard, J. Johns, M. Harold & L. Malik. Breast Cancer Research and Treatment, 2020.

  • Hyperprogressive disease in early‐phase immunotherapy trials: Clinical predictors and association with immune‐related toxicities. Y. Kanjanapan, D. Day, L. Wang, H. Al‐Sawaihey, E. Abbas, A. Namini, L.L. Siu, A. Hansen, A.A. Razak, A. Spreafico, N. Leighl, A.M. Joshua, M.O. Butler, D. Hogg, M.A. Chappell, L. Soultani, K. Chow, S. Boujo & P.L. Bedard. Cancer, 2019; 125(8): 1341-1349.

  • Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials. Y. Kanjanapan, D. Day, M.O. Butler, L. Wang, A.M. Joshua, D. Hogg, N.B. Leighl, A.R. Abdul Razak, A. Hansen, S. Boujos, M. Chappell, K.Chow, B. Sherwin, L.A. Stayner, L. Soultani, A. Zambrana, L.L. Siu, L.Bedard & A. Spreafico. European Journal of Cancer; 2019; 107: 1-7.

  • Novel patterns of response under immunotherapy. Borcoman, Y. Kanjanapan, S. Champiat, S. Kato, V. Servois, R. Kurzrock, S. Goel, P. Bedard & C. Le Tourneau. Annals of Oncology, 2019; 30: 385-396.

Special Interests

Dr Yada Kanjanapan accepts referrals for all cancer types, with a special clinical interest in:

  • Breast cancer
  • Gynaecological cancer
  • Melanoma

Languages spoken

  • English
  • Mandarin
  • Thai

Icon Locations

Visiting Locations

  • Canberra Hospital

Affiliations & Memberships

  • Australia and New Zealand Breast Cancer Trials Group (ANZBCTG)
  • Australia New Zealand Gynaecological Oncology Group (ANZGOG)
  • American Society of Clinical Oncology (ASCO)
  • Medical Oncology Group of Australia (MOGA)
  • Royal Australasian College of Physicians (RACP)

Publications

  • Real-world analysis of breast cancer patients qualifying for adjuvant CDK4/6 inhibitors, Clinical Breast Cancer. Kanjanapan Y, Anderson, W, Smith M, Green J, Chalker E, Craft P.  Clinical Breast Cancer, 2024.

  • Response to COVID-19 vaccination in patients on cancer therapy: Analysis in a SARS-CoV-2-naïve population. Cavic G, Almonte A, Hicks M, Neeman T, Wang JW, Brew S, Choi PY, Cockburn I, Gardiner E, Yip D, Fahrer A, Kanjanapan Y. Asia-Pacific Journal of Clinical Oncology, 2024.

  • Impact of prior (neo)adjuvant trastuzumab exposure on the efficacy of HER2 targeted therapy for metastatic breast cancer. Y. Kanjanapan,  D. Tran, S.W. Lok, P.Gibbs, R. De Boer, B. Yeo, S. Greenberg, F. Barnett, L. Nott, G. Richardson, R. Wong, M. Nottage, I. Collins, J. Torres, J. Lombard, J. Johns, M. Harold & L. Malik. Breast Cancer Research and Treatment, 2020.

  • Hyperprogressive disease in early‐phase immunotherapy trials: Clinical predictors and association with immune‐related toxicities. Y. Kanjanapan, D. Day, L. Wang, H. Al‐Sawaihey, E. Abbas, A. Namini, L.L. Siu, A. Hansen, A.A. Razak, A. Spreafico, N. Leighl, A.M. Joshua, M.O. Butler, D. Hogg, M.A. Chappell, L. Soultani, K. Chow, S. Boujo & P.L. Bedard. Cancer, 2019; 125(8): 1341-1349.

  • Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials. Y. Kanjanapan, D. Day, M.O. Butler, L. Wang, A.M. Joshua, D. Hogg, N.B. Leighl, A.R. Abdul Razak, A. Hansen, S. Boujos, M. Chappell, K.Chow, B. Sherwin, L.A. Stayner, L. Soultani, A. Zambrana, L.L. Siu, L.Bedard & A. Spreafico. European Journal of Cancer; 2019; 107: 1-7.

  • Novel patterns of response under immunotherapy. Borcoman, Y. Kanjanapan, S. Champiat, S. Kato, V. Servois, R. Kurzrock, S. Goel, P. Bedard & C. Le Tourneau. Annals of Oncology, 2019; 30: 385-396.

Search

Contact us
Become a patient